Clinical Translation of Anti-PECAM-1 Monoclonal Antibody as an

Award Information
Agency:
Department of Health and Human Services
Amount:
$198,751.00
Program:
SBIR
Contract:
N43CO201000116
Solitcitation Year:
2010
Solicitation Number:
PHS2010-1
Branch:
N/A
Award Year:
2010
Phase:
Phase I
Agency Tracking Number:
N43CO201000116
Solicitation Topic Code:
NCI
Small Business Information
GENOMIC SYSTEMS, LLC
GENOMIC SYSTEMS, LLC, 290 LOWELL AVE, PALO ALTO, CA, 94301
Hubzone Owned:
N
Woman Owned:
N
Socially and Economically Disadvantaged:
N
Duns:
825061778
Principal Investigator
 Robert Debs
 () -
Business Contact
Phone: (650) 906-5631
Research Institution
N/A
Abstract
Most patients who die from cancer succumb to advanced metastatic cancer. These patients, are mostoften treatment-refractory, and comprise the largest untapped market in cancer. We have developed a uniquely effective anti-PECAM-1 monoclonal antibody (mAb)-based therapy. To our knowledge, this mAb is the only treatment that safely and effectively treats advanced tumor metastases, independent of tumor type. Clinical translation of anti-PECAM-1 mAb therapy could revolutionize the treatment of this now-refractory clinical entity. Therefore, we propose to perform the following pre-clinical studies required to translate antiPECAM- 1 mAb-based therapy into phase I clinical trials in cancer patients.

* information listed above is at the time of submission.

Agency Micro-sites

US Flag An Official Website of the United States Government